NVAX Q2 2023 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena

NVAXNovavax, Inc.

$2B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$424M+128.3% YoY

Gross Profit

$369M86.9% margin

Operating Income

$55M13.1% margin

Net Income

$58M13.7% margin

EPS (Diluted)

$0.58

QoQ Revenue Growth

+6702.8%

Cash Flow

Operating Cash Flow

-$172M

Free Cash Flow

-$180M

Stock-Based Comp.

$20M

Balance Sheet

Total Assets

$1.7B

Total Liabilities

$2.4B

Stockholders' Equity

-$755M

Cash & Equivalents

$506M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$424M	$186M	+128.3%
Gross Profit	$369M	-$85M	+532.9%
Operating Income	$55M	-$483M	+111.5%
Net Income	$58M	-$510M	+111.4%

Revenue Segments

Product

$285M67%

Grant

$137M32%

Royalties and Other

$2M1%

Geographic Segments

Rest of the World

$284M99%

Europe

$2M1%